Problems › Business Transformation Consulting › Education & Training Providers
Most transformation programmes fail in the diagnosis, and the diagnosis is usually bought from the people who will be paid to deliver the answer. This page works through it for education and training providers specifically — including an unedited excerpt from a real analysis of an education and training provider.
Most transformation programmes fail in the diagnosis, and the diagnosis is usually bought from the people who will be paid to deliver the answer. For education and training providers, this shows up in a particular place. The numbers that carry the answer are 14.4 % and 71 %, and the complication specific to this industry is that to reach 13.44 m usd revenue requires 6,720 enrolments yet incremental support costs erase 0.17 m usd of ebitda. The general version of this problem and the one you are actually in have different first moves.
A transformation engagement bundles three separable things: finding out what is wrong, deciding what to do about it, and having enough hands to do it. Firms sell them together because that is how the economics work — the diagnostic phase is priced near cost and earns its money by scoping the delivery phase that follows. That is not a scandal, it is a business model, but it has a consequence worth understanding before you sign. The people producing your diagnosis are commercially better off if the diagnosis is large.
The published failure rates for these programmes have hovered around 70% for thirty years, which is itself informative. A discipline that fails most of the time at something it has practised for decades is not failing at execution. It is usually failing earlier, at the point where a genuine question — which parts of this business earn their cost of capital, and which of them can we actually change this year — got converted into a workstream plan before it was answered.
The practical test is whether you can currently name the two or three things that are wrong, in the order you would fix them, with the arithmetic attached. If you can, you have a delivery problem, and buying delivery capacity is a rational purchase. If you cannot, you have a diagnosis problem, and every pound spent on delivery capacity before the diagnosis exists is a pound spent making the wrong change more thoroughly.
Corporate Strategy & Transformation (catalog id t5) is the analysis that produces the first half: what the portfolio actually looks like once cost and capital are allocated honestly, which units are funding which, what changes and in what order. It does not put people on the ground and does not pretend to. Where the honest answer is that you need forty consultants for nine months, it will say so — which is a cheaper way to find that out than the first invoice.
These three together are the signature. One on its own usually points somewhere else.
✓ The word "transformation" is being used before anyone has agreed what is broken
✓ A scoping document exists and a diagnosis does not
✓ The programme has workstreams named after departments rather than after problems
The move that usually makes it worse. Buying the diagnosis from the firm that will bid to deliver the remedy, which reliably produces a diagnosis with a large remedy attached.
It is for you if you run or finance an education and training provider and the word "transformation" is being used before anyone has agreed what is broken. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on an education and training provider. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is Brightsel Learning Group, a sample company profile used for testing rather than a customer — 11.52 m USD revenue from 5,760 enrolments.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Monetise the existing 48 contracts by adding regulatory add-ons delivered at the physical sites to lift ACV 25–30 % and protect margin.
| Investment required | 0.35–0.45 m USD (within the stated 0.85 m USD FY2026 cap) |
| Expected return | Base case incremental EBITDA of 0.45–0.55 m USD on 0.40 m USD investment yields 1.1–1.4× payback within 18 months; upside case reaches 1.8× if 5 new contracts are added by Month 24. |
| Revenue, year 1 | 12.4–12.7 m USD |
| Revenue, year 2 | 13.3–14.0 m USD |
| Revenue, year 3 | 14.5–15.5 m USD |
| Exit criteria | Strategy abandoned if, by Month 12, fewer than 50 % of the 48 contracts have renewed at the 25 % premium OR if instructor utilisation falls below 65 % for two consecutive quarters, signalling demand or capacity failure. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Corporate Strategy & Transformation, one of 29 engagements the platform runs. For education and training providers it works through 14.4 %, 71 %, 18.3 % and 312 USD, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
For a mid-market company the diagnostic phase alone is commonly £75k–£250k over six to ten weeks, and the delivery phase that follows is usually several multiples of that. Large-firm day rates run roughly £1,500–£3,500 for a consultant and £4,000–£8,000 for a partner, and a typical team blends the two so the effective rate lands somewhere in the middle. The number that matters is not the day rate, though — it is the ratio of diagnosis to delivery, because that is where the scope is set.
No, and any tool that claims otherwise is selling you something. Software cannot run a programme office, hold a difficult conversation with a divisional MD, or supply forty people for nine months. What it can do is produce the analysis that decides whether you need those things, and what they should be pointed at — which is the part that is most often rushed and most expensive to get wrong.
Buy the diagnosis separately from whoever will deliver, and write the decision down before you take delivery bids. Once the two or three changes are named and the arithmetic is on paper, the delivery tender is a procurement exercise with a fixed brief. Once they are not, the tender sets its own brief, and it is always a larger one.
Materially, yes. To reach 13.44 m usd revenue requires 6,720 enrolments yet incremental support costs erase 0.17 m usd of ebitda — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are 14.4 %, 71 %, 18.3 %, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on 14.4 % and 71 %. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.